Abstract

Aim: Recurrent nasopharyngeal carcinoma (NPC) after previous radiation therapy is a major problem. This study was conducted to determine the survival benefits and potential benefits of the effects of severe late toxicities by re-irradiation with fractionated stereotactic radiotherapy (FSRT).Material and Methods: 2009-2018, treatment outcomes were evaluated retrospectively in 26 patients with local recurrent NPC were cured applying FSRT with Cyberknife. Five patients had metastatic disease and one had second recurrence was excluded from the research, remaining 20 patients were analyzed. Median agewas 52 years (range,28-80 years), re-treatment T stagewas; 6 (30%) T2, 5 (25%) T3, 9 (45%) T4.Median time from initial RT to recurrence was 22 months (range,8-159 mo.). The median re-irradiation FSRT dose was 30Gy in 5 fractions.Results: Median follow-up was44 (22-179)months, the overall survival(OS) rate, local failure-free survival (LFFS ) and disease progression-free survival(DPFS) rate at 3 years were 89%,73% and 53%, respectively. All patients were evaluated for response after treatment; 9 (45%) had complete, 3 (15%) partial, 6 (%30) had no response.Univariate analysis demonstrated that; higher cumulative total radiotherapy dose, gross tumor volume and recurrent time interval were prognostic factors for LFFS. Recurrent time interval was also independent factor for DPFS and OS. The incidence of temporal lobe necrosis and trismus were 10% and 20%,respectively. One patient had grade 5 toxicity to treatment related bleeding.Conclusion: Tumor dose coverage is critical for treating recurrent NPC and treatment linked death rate was vascular in nature. Fractionated stereotactic radiotherapy is promising treatment modality for recurrent NPC.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.